Form 4: Cardiff Oncology's Chief Scientific Officer, Tod Smeal, Reports Stock Option Grant
SEC Form 4 Filing
Tod Smeal, Chief Scientific Officer of Cardiff Oncology, reports the acquisition of stock options.
Summary
- On March 11, 2025, Tod Smeal, the Chief Scientific Officer of Cardiff Oncology, Inc., was granted stock options to purchase 332,621 shares of common stock at an exercise price of $3.58.
- These options vest over time, with 25% vesting on March 11, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.
- Following this transaction, Smeal directly owns 979,805 shares of Cardiff Oncology's common stock.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The vesting schedule suggests a long-term commitment from the executive.
Positives
- The grant of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's success.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The vesting schedule of the stock options suggests an expectation of continued service and contribution from the Chief Scientific Officer over the next several years.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company. This is especially true for companies like Cardiff Oncology that are in the research and development phase.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals routinely use stock options to incentivize their executives.
- The vesting schedule and exercise price are generally determined based on industry benchmarks and the executive's role and responsibilities.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.
- Employees may see this as a sign of stability and investment in key personnel.
Key Dates
| Date | Description |
|---|---|
| 03/11/2025 | Date of the stock option grant and earliest transaction date. |
| 03/11/2026 | Date when 25% of the stock options begin to vest. |
| 03/13/2025 | Date of the Form 4 filing. |
| 03/11/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.